Luye Pharma has announced the acquisition of two investigational biological antibodies being developed by Shandong Boan Biological Technology Co., Ltd. Luye Pharma has a carefully formulated strategy ...
Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma’s Xuezhikang Capsules in mainland...
Luye Pharma Group has announced that its Central Nervous System (CNS) drug, Seroquel XR (Quetiapine Fumarate XR), has received approval from the official Chinese medical authorities for a new indicati...
Luye Pharma Group has announced that the company’s new compound candidate, extended release tablet ‘LY03012’, a China Class 1 new chemical drug, has been approved by the National Med...
On September 4, Luye Pharma announced that its independently developed drug, Goserelin Acetate Extended-release Microspheres for Injection (LY01005), has entered phase III clinical trials for prostate...
Luye Pharma Group has announced that import registration procedures for one of the company’s core central nervous system (CNS) products, ‘Rivastigmine Transdermal Patches’, have been...
On June 22nd in Hong Kong, Luye Pharma Group hosted a conference to unveil their Global Collaboration Strategy. Liu Dianbo, Chairman of Luye Pharma Group, said at the event, “Starting in 2019, Luye P...
SINGAPORE, 10 April 2018 – Luye Medical Group (the “Company”), a leading pan-Asian healthcare services provider, announced that it has recently completed a majority equity investment in Novena...
Luye Pharma announced that its new investigational drug, Rotigotine Extended Release Microspheres for Injection (LY03003) for the treatment of Parkinson’s disease has been submitted to the Pharm...
Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today announced that it has entered the final stage of New Drug A...
TOP